Company news

InflaRx N.V. news in 2021

InflaRx N.V.'s news releases, calls and decks from 2021, newest first.

View company

InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)

November 14, 2021

InflaRx Reports Third Quarter 2021 Financial & Operating Results

November 4, 2021

InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

October 26, 2021

InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19

October 11, 2021

InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

September 7, 2021

InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum

August 9, 2021

InflaRx Reports Second Quarter 2021 Financial & Operating Results

August 4, 2021

InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab

June 7, 2021

Tony Gibney Joins InflaRx Board of Directors

May 20, 2021

InflaRx Reports First Quarter 2021 Financial & Operating Results

May 11, 2021

InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study

May 10, 2021

InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum

April 14, 2021

InflaRx Reports Full Year 2020 Financial & Operating Results

March 24, 2021

InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants

February 28, 2021

InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants

February 24, 2021

InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants

February 23, 2021

InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference

February 10, 2021

InflaRx Provides Update on Vilobelimab (IFX-1) Development

January 10, 2021

InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis

January 4, 2021

Decks in 2021